新氟喹诺酮类抗生素昌欣沙星的药效学研究
|
摘要
喹诺酮类抗生素作为目前我国临床治疗感染性疾病的重要药物之一,具有抗菌谱广、抗菌活性强、药代动力学特性好等特点,尤其氟喹诺酮类抗生素具有更大的优势。从喹诺酮类抗生素发现至今,已有数十种新喹诺酮类化合物进入临床,当前广泛使用的环丙沙星、氧氟沙星、左氧氟沙星、莫西沙星等是临床抗感染不可或缺的药物。昌欣沙星是由我国自主研发的1.1类新氟喹诺酮类抗生素,是由莫西沙星进行结构改造,将8位二氟甲氧基取代甲氧基而得,具有良好的体内外广谱抗菌活性。
本论文第一部分研究了昌欣沙星的体外药效学,包括对1754株临床分离菌的MIC分布、MBC、KCs、抗菌活性影响因素、细胞毒性和对DNA回旋酶和拓扑异构酶Ⅳ的抑制试验。结果表明,昌欣沙星对革兰氏阳性菌和革兰氏阴性菌均具有较强的广谱抗菌活性,对肺炎链球菌、流感嗜血杆菌具有非常强的抗菌活性,MIC90分别为0.25μg/mL、0.03μg/mL,与莫西沙星相当或稍强,对金葡菌、表葡菌、化脓链球菌、粪肠球菌、肺炎克雷伯杆菌的MIC5o为0.06～0.5μg/mL之间,显示出良好的活性。昌欣沙星对临床耐药菌仍有较好的抗菌活性,对MRSA、CR-MRSA、MRSE、CR-MRSE、PISP、PRSP等的MICso为0.125～4μg/mL之间,对产ESBL的大肠埃希菌和肺炎克雷伯杆菌的活性稍弱,但仍与莫西沙星相当。昌欣沙星对金葡菌、肺炎链球菌、流感嗜血杆菌、副流感嗜血杆菌的敏感率较高,分别为52.3%、97.8%、100%和86.5%,具有较好的临床使用前景。MBC试验和杀菌曲线试验结果表明,昌欣沙星对金葡菌、化脓链球菌、肺炎链球菌、大肠埃希菌、肺炎克雷伯杆菌是一种有效的杀菌剂,对金葡菌、肺炎链球菌、大肠埃希菌、肺炎克雷伯杆菌的杀菌效果呈现明显的浓度依赖关系,对化脓链球菌呈现时间依赖关系,有待于进一步研究。影响因素试验表明,培养基pH值、细菌接种量、血清浓度等对昌欣沙星的抗菌活性无明显影响。
细胞毒性试验结果表明,昌欣沙星对人肺腺癌A549细胞毒性较小,IC5o为551.04μg/mL(大于1000μM),与莫西沙星等其他临床常用喹诺酮类化合物相当。
昌欣沙星对喹诺酮类靶点DNA回旋酶和拓扑异构酶Ⅳ的抑制试验表明,昌欣沙星对DNA回旋酶的促旋活性抑制的IC5o为1.05μM,稍弱于莫西沙星,但与环丙沙星相当；对拓扑异构酶Ⅳ的解离活性抑制的IC5o为2.25μM,弱于莫西沙星和环丙沙星；松弛活性抑制的IC5o为0.79μM,强于莫西沙星和环丙沙星。
此外,为更深入的研究昌欣沙星的药效学,克隆表达了金葡菌中喹诺酮类抗生素的靶点之一的拓扑异构酶Ⅳ,为进一步研究昌欣沙星的作用机制打下了基础。
本论文第二部分研究了昌欣沙星的体内药效学。在小鼠全身感染模型中,昌欣沙星口服给药与莫西沙星口服给药治疗效果相当,对革兰氏阳性菌优于左氧氟沙星,对革兰氏阴性菌弱于左氧氟沙星。其中对金葡菌、肺炎链球菌、大肠埃希菌、肺炎克雷伯杆菌杆菌引起的全身感染具有较好的治疗效果,ED5o为1.25 mg/kg至8.28 mg/kg;对粪肠球菌引起的全身感染治疗效果稍差,EDso为25.02 mg/kg o
同时,研究了昌欣沙星在小鼠体内的药代动力学特点,通过计算昌欣沙星5 mg/kg口服给药后小鼠体内的药代动力学参数,得到昌欣沙星在小鼠体内的Cmax为1085ng/mL,半衰期为1.425h,AUC0-24h为1101.31h*ng/mL。根据体外药效学MIC数据计算获得金葡菌、肺炎链球菌、肺炎克雷伯杆菌、流感嗜血杆菌、副流感嗜血杆菌的Cmax/MIC50分别为18.08、8.68、4.34、135.625、31.17,化脓链球菌的T>MIC为2.03h。试验结果说明昌欣沙星具有良好的药代动力学特征,进一步说明昌欣沙星具有良好的体内抗菌能力。
Quinolone antibiotics are important kind of medicines dealing with clinical infectious diseases in China, which are broad-spectrum, highly potent and have good pharmacokinetics parameters, especially the fluoroquinolones which are more effective. Since the discovery of the quinolones, there are several scores of ones with new structure being used in clinical. Ciprofloxacin, ofloxacin, levofloxacin and moxifioxaxin are enssential in the treatment of infection. Chinfloxacin is a Class I new quinolone drug developed by our country, which is the difluoride substitution of moxifloxacin in the 8-methoxy group, and it shows broad-spectrum activities against bacteria in vitro and in vivo.
In the first part of this work, the in vitro pharmacodynamics characteristics of Chinfloxacin were studied to 1756 clinical isolates and standard isolates, including the MICs, MBC, KCs, incubation conditions'effects, cytotoxic and inhibition test against DNA gyrase and topoisomerase IV. The result demonstrated that Chinfloxacin had good antibacterial activity against both Gram-positive and Gram-negative organisms, notablely the antibacterial activity against S. pneumoniae, H. influenzae were extremely good, MIC90S were 0.25μg/mL、0.03μg/mL, which were equal to or better than moxifloxacin. Besides, the MIC50S of Chinfloxacin against the other frequent clinical isolates such as S. aureus, S. epidermidis, S. pyogenes, E. faecalis and K. pneumoniae were between 0.06μg/mL to 0.5μg/mL, showed good activities too. Chinfloxacin had relatively good antibacterial activity to clinical drug-resistant isolates. The MIC50S against MRSA, CR-MRSA, MRSE, CR-MRSE, PISP and PRSP were from 0.125μg/mL to 4μg/mL. The activities of Chinfloxacin against ESBL- E. coli and ESBL-K. pneumonia were slightly week, but still equal to that of moxifloxacin. The susceptible rates of Chinfloxacin to S. aureus, S. pneumoniae, H. influenzae and H. parainfluenzae were quite high, which were 52.3%,97.8%,100% and 86.5%, showed good potential. MBC experiment and KCs experiment revealed that Chinfloxacin was an effective bactericidal agent against S. aureus, S. pyogenes, S. pneumoniae, E. coli and K. pneumoniae. The activities of Chinfloxacin against S. aureus, S. pneumoniae, E. coli and K. pneumoniae were concentration dependent, but were time dependent against S. pyogenes, which should be studied later. The pH, inoculum size and serum concentration had no apparent effects on the activity of Chinfloxacin.
The cytotoxicity experiment showed that Chinfloxacin was safe to human adenocarcinoma lung cell A549, with IC50 551.04μg/mL (more than 1000μM), which was similar to the other quinolones usually used in clinical.
The inhibition test of Chinfloxacin against DNA gyrase and topoisomerase IV, the target of the quinolone, revealed that the IC50 of Chinfloxacin in the supercoling inhibition test is 1.05μM, a little weak than moxifloxacin, but equal to ciprofloxacin. The IC50 of Chinfloxacin in the decatenation inhibition test is 2.25μM, which is inferior than moxifloxacin and ciprofloxacin. Then the IC50 of Chinfloxacin in the relaxation inhibition test is 0.79μM, which is superior than moxifloxacin and ciprofloxacin.
Besides, to do some further research, we express the topoisomeraseⅣof S. aureus, one of the target of quinolones. We purified the two submits of the enzyme, quantitate the concentration and then determined the activity of the enzyme, to do the groundwork for the further research of the mechanism of action.
In the second part of this work, the in vivo pharmacodynamics of Chinfloxacin was studied. In the mouse systemic infection model, Chinfloxacin showed the same therapeutic efficacy with moxifloxacin by oral administration, which is better than levofloxacin against Gram-positive bacteria, and is inferior than levofloxacin against Gram-negative bacteria. Chinfloxacin showed good efficacy against S. aureus, S. pneumoniae, E. coli and K. pneumoniae, with ED50s 1.25 mg/kg to 8.28 mg/kg, and showed weaker efficacy against E. faecalis in vivo, with ED50 25.02 mg/kg.
Meanwhile the pharmacokinetics of Chinfloxacin in mouse was studied. The Cmax, T1/2, AUC0-24h were 1085ng/mL,1.425h,1101.31h*ng/mL respectively calculated by the pharmacokinetics parameters of mouse after oral administration of Chinfloxacin. On the basis of the MIC in vitro, we obtained the Cmax/MIC50 of S. aureus, S. pneumoniae, K. pneumoniae, H. influenzae and H. parainfluenzae which were 18.08、8.68、4.3、135.625、31.17 respectively, and the T>MIC50 of S. pyogenes was 2.03h. The results demonstrate that Chinfloxacin had good pharmacokinetics performance, and revealed the good antibacterial potential in vivo.
本论文第一部分研究了昌欣沙星的体外药效学,包括对1754株临床分离菌的MIC分布、MBC、KCs、抗菌活性影响因素、细胞毒性和对DNA回旋酶和拓扑异构酶Ⅳ的抑制试验。结果表明,昌欣沙星对革兰氏阳性菌和革兰氏阴性菌均具有较强的广谱抗菌活性,对肺炎链球菌、流感嗜血杆菌具有非常强的抗菌活性,MIC90分别为0.25μg/mL、0.03μg/mL,与莫西沙星相当或稍强,对金葡菌、表葡菌、化脓链球菌、粪肠球菌、肺炎克雷伯杆菌的MIC5o为0.06～0.5μg/mL之间,显示出良好的活性。昌欣沙星对临床耐药菌仍有较好的抗菌活性,对MRSA、CR-MRSA、MRSE、CR-MRSE、PISP、PRSP等的MICso为0.125～4μg/mL之间,对产ESBL的大肠埃希菌和肺炎克雷伯杆菌的活性稍弱,但仍与莫西沙星相当。昌欣沙星对金葡菌、肺炎链球菌、流感嗜血杆菌、副流感嗜血杆菌的敏感率较高,分别为52.3%、97.8%、100%和86.5%,具有较好的临床使用前景。MBC试验和杀菌曲线试验结果表明,昌欣沙星对金葡菌、化脓链球菌、肺炎链球菌、大肠埃希菌、肺炎克雷伯杆菌是一种有效的杀菌剂,对金葡菌、肺炎链球菌、大肠埃希菌、肺炎克雷伯杆菌的杀菌效果呈现明显的浓度依赖关系,对化脓链球菌呈现时间依赖关系,有待于进一步研究。影响因素试验表明,培养基pH值、细菌接种量、血清浓度等对昌欣沙星的抗菌活性无明显影响。
细胞毒性试验结果表明,昌欣沙星对人肺腺癌A549细胞毒性较小,IC5o为551.04μg/mL(大于1000μM),与莫西沙星等其他临床常用喹诺酮类化合物相当。
昌欣沙星对喹诺酮类靶点DNA回旋酶和拓扑异构酶Ⅳ的抑制试验表明,昌欣沙星对DNA回旋酶的促旋活性抑制的IC5o为1.05μM,稍弱于莫西沙星,但与环丙沙星相当；对拓扑异构酶Ⅳ的解离活性抑制的IC5o为2.25μM,弱于莫西沙星和环丙沙星；松弛活性抑制的IC5o为0.79μM,强于莫西沙星和环丙沙星。
此外,为更深入的研究昌欣沙星的药效学,克隆表达了金葡菌中喹诺酮类抗生素的靶点之一的拓扑异构酶Ⅳ,为进一步研究昌欣沙星的作用机制打下了基础。
本论文第二部分研究了昌欣沙星的体内药效学。在小鼠全身感染模型中,昌欣沙星口服给药与莫西沙星口服给药治疗效果相当,对革兰氏阳性菌优于左氧氟沙星,对革兰氏阴性菌弱于左氧氟沙星。其中对金葡菌、肺炎链球菌、大肠埃希菌、肺炎克雷伯杆菌杆菌引起的全身感染具有较好的治疗效果,ED5o为1.25 mg/kg至8.28 mg/kg;对粪肠球菌引起的全身感染治疗效果稍差,EDso为25.02 mg/kg o
同时,研究了昌欣沙星在小鼠体内的药代动力学特点,通过计算昌欣沙星5 mg/kg口服给药后小鼠体内的药代动力学参数,得到昌欣沙星在小鼠体内的Cmax为1085ng/mL,半衰期为1.425h,AUC0-24h为1101.31h*ng/mL。根据体外药效学MIC数据计算获得金葡菌、肺炎链球菌、肺炎克雷伯杆菌、流感嗜血杆菌、副流感嗜血杆菌的Cmax/MIC50分别为18.08、8.68、4.34、135.625、31.17,化脓链球菌的T>MIC为2.03h。试验结果说明昌欣沙星具有良好的药代动力学特征,进一步说明昌欣沙星具有良好的体内抗菌能力。
Quinolone antibiotics are important kind of medicines dealing with clinical infectious diseases in China, which are broad-spectrum, highly potent and have good pharmacokinetics parameters, especially the fluoroquinolones which are more effective. Since the discovery of the quinolones, there are several scores of ones with new structure being used in clinical. Ciprofloxacin, ofloxacin, levofloxacin and moxifioxaxin are enssential in the treatment of infection. Chinfloxacin is a Class I new quinolone drug developed by our country, which is the difluoride substitution of moxifloxacin in the 8-methoxy group, and it shows broad-spectrum activities against bacteria in vitro and in vivo.
In the first part of this work, the in vitro pharmacodynamics characteristics of Chinfloxacin were studied to 1756 clinical isolates and standard isolates, including the MICs, MBC, KCs, incubation conditions'effects, cytotoxic and inhibition test against DNA gyrase and topoisomerase IV. The result demonstrated that Chinfloxacin had good antibacterial activity against both Gram-positive and Gram-negative organisms, notablely the antibacterial activity against S. pneumoniae, H. influenzae were extremely good, MIC90S were 0.25μg/mL、0.03μg/mL, which were equal to or better than moxifloxacin. Besides, the MIC50S of Chinfloxacin against the other frequent clinical isolates such as S. aureus, S. epidermidis, S. pyogenes, E. faecalis and K. pneumoniae were between 0.06μg/mL to 0.5μg/mL, showed good activities too. Chinfloxacin had relatively good antibacterial activity to clinical drug-resistant isolates. The MIC50S against MRSA, CR-MRSA, MRSE, CR-MRSE, PISP and PRSP were from 0.125μg/mL to 4μg/mL. The activities of Chinfloxacin against ESBL- E. coli and ESBL-K. pneumonia were slightly week, but still equal to that of moxifloxacin. The susceptible rates of Chinfloxacin to S. aureus, S. pneumoniae, H. influenzae and H. parainfluenzae were quite high, which were 52.3%,97.8%,100% and 86.5%, showed good potential. MBC experiment and KCs experiment revealed that Chinfloxacin was an effective bactericidal agent against S. aureus, S. pyogenes, S. pneumoniae, E. coli and K. pneumoniae. The activities of Chinfloxacin against S. aureus, S. pneumoniae, E. coli and K. pneumoniae were concentration dependent, but were time dependent against S. pyogenes, which should be studied later. The pH, inoculum size and serum concentration had no apparent effects on the activity of Chinfloxacin.
The cytotoxicity experiment showed that Chinfloxacin was safe to human adenocarcinoma lung cell A549, with IC50 551.04μg/mL (more than 1000μM), which was similar to the other quinolones usually used in clinical.
The inhibition test of Chinfloxacin against DNA gyrase and topoisomerase IV, the target of the quinolone, revealed that the IC50 of Chinfloxacin in the supercoling inhibition test is 1.05μM, a little weak than moxifloxacin, but equal to ciprofloxacin. The IC50 of Chinfloxacin in the decatenation inhibition test is 2.25μM, which is inferior than moxifloxacin and ciprofloxacin. Then the IC50 of Chinfloxacin in the relaxation inhibition test is 0.79μM, which is superior than moxifloxacin and ciprofloxacin.
Besides, to do some further research, we express the topoisomeraseⅣof S. aureus, one of the target of quinolones. We purified the two submits of the enzyme, quantitate the concentration and then determined the activity of the enzyme, to do the groundwork for the further research of the mechanism of action.
In the second part of this work, the in vivo pharmacodynamics of Chinfloxacin was studied. In the mouse systemic infection model, Chinfloxacin showed the same therapeutic efficacy with moxifloxacin by oral administration, which is better than levofloxacin against Gram-positive bacteria, and is inferior than levofloxacin against Gram-negative bacteria. Chinfloxacin showed good efficacy against S. aureus, S. pneumoniae, E. coli and K. pneumoniae, with ED50s 1.25 mg/kg to 8.28 mg/kg, and showed weaker efficacy against E. faecalis in vivo, with ED50 25.02 mg/kg.
Meanwhile the pharmacokinetics of Chinfloxacin in mouse was studied. The Cmax, T1/2, AUC0-24h were 1085ng/mL,1.425h,1101.31h*ng/mL respectively calculated by the pharmacokinetics parameters of mouse after oral administration of Chinfloxacin. On the basis of the MIC in vitro, we obtained the Cmax/MIC50 of S. aureus, S. pneumoniae, K. pneumoniae, H. influenzae and H. parainfluenzae which were 18.08、8.68、4.3、135.625、31.17 respectively, and the T>MIC50 of S. pyogenes was 2.03h. The results demonstrate that Chinfloxacin had good pharmacokinetics performance, and revealed the good antibacterial potential in vivo.
引文
1. 何建鹏,李日生,刘厚凡,马李秀,陈卫军,席鹏：喹诺酮类药物的发展概况.江西化工[J].2007(3)：17-18.
2. 赵汝霞,虞亦鸣：喹诺酮类药物的研究进展.临床肺科杂志[J].2010,15(12)：1769-1770.
3. Drlica K, Malik M, Kerns RJ, Zhao X:Quinolone-Mediated Bacterial Death. Antimicrobial Agents and Chemotherapy[J].2007,52(2):385-392.
4. Ruiz J:Mechanisms of resistance to quinolones:target alterations, decreased accumulation and DNA gyrase protection. Journal of Antimicrobial Chemotherapy [J].2003, 51(5):1109-1117.
5. 张英,赵志刚,张杰：莫西沙星-一种新的氟喹诺酮类药物.中国临床药理学杂志[J].2002,18(5)：396-400.
6. 柴芸：新氟喹诺酮类抗菌药西他沙星.国外医药抗生素分册[J].2009,30(6)：264-270.
7. J萨姆布鲁克,DW拉塞尔：分子克隆试验指南[M].北京：科学出版社,2002.
8. CLSI. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard-eighth edition. [S] CLSI document M07-A8. Wayne, PA: Clinical and Laboratory Standards Institute,2009.
9.张丽龙；粟永萍；刘晓宏；程天民；郑虎；翁玲玲；艾国平：第三军医大学学报[J].2006,28(13)：1393-1396
10. Black MT, Stachyra T, Platel D, Girard AM, Claudon M, Bruneau JM, Miossec C: Mechanism of Action of the Antibiotic NXL101, a Novel Nonfluoroquinolone Inhibitor of Bacterial Type Ⅱ Topoisomerases. Antimicrobial Agents and Chemotherapy[J].2008, 52(9):3339-3349.
11. Yoshihiro Oyamada J-iY:Mechanism of inhibition of DNA gyrase by ES-1273, a novel DNA gyrase inhibitor. Microbiol Immunol [J].2007,50(10):977-984.
12. Mary-Ann Bjornsti and Neil Osheroff, Methods in Molecular Biology.Vol.94[M]. USA:Humana press,1999,1st edition
13. Mary-Ann Bjornsti and Neil Osheroff, Methods in Molecular Biology.Vol.95[M].USA:Humana press,1999,1st edition
14.徐佳骏,崔岚：新型喹诺酮类抗菌药加雷沙星.中国新药杂志[J].2008,17(20)：1808-1810.
15.柴芸,刘秉全,郭慧元：喹诺酮的结构修饰及药理活性研究新进展.中国新药杂志[J].2007,16(14)：1068-1074.
16.杨信怡：重组溶葡球菌酶抗菌药效学及耐药机制研究[D].北京：北京协和医学院,2005.
17.王宇明：感染病学[M].北京：人民卫生出版社2010,216-241
18.王睿：氟喹诺酮类PK-PD的研究进展.中国新药杂志[J]2002,11(11)：884-887.
19. Bichsel A, James CW, Gurk-Turner C:Fluoroquinolone drug class update. PHARMACOLOGY NOTES[J].2000(13):289-292.
20.李聪然：新氨基糖苷类抗生素威替米星的药效学及其对重组氨基糖苷类双功能修饰酶的稳定性[D]北京,北京协和医学院,2006.
21.王洪允：生物样本中药物定量分析的规范和要求.2011年高级临床药理Ⅰ期研究高级培训班[A],2011,58-94
22.杨信怡：重组溶葡球菌酶抗菌药效学及耐药机制研究[D]北京,北京协和医学院,2005.
23. Odenholt I, Cars O:Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli:simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model. Journal of Antimicrobial Chemotherapy[J] 2006,58(5):960-965.
1. 张致平：喹诺酮类抗菌药研究的进展.中国抗生素杂志[J].1992,17(2)：87-97.
2. 张致平：喹诺酮类抗菌药研究的新进展.引进国外技术与设备[J].1995,1(4)：216-222.
3. Rowen RC, Michel DJ, Thompson JC:Norfloxacin:clinical pharmacology and clinical use. Pharmacotherapy[J].1987,7(4):92-110.
4. Ito A, Hirai K, Inoue M, Koga H, Suzue S, Irikura T, Mitsuhashi S:In vitro antibacterial activity of AM-715, a new nalidixic acid analog. Antimicrob Agents Chemother[J].1980, 17(2):103-108.
5. Wang C, Sabbaj J, Corrado M, Hoagland V:World-wide clinical experience with norfloxacin:efficacy and safety. Scand J Infect Dis Suppl [J].1986,48:81-89.
6. Wise R:Norfloxacin--a review of pharmacology and tissue penetration. J Antimicrob Chemother[J].1984,13 Suppl B:59-64.
7. Ball P:Adverse reactions and interactions of fluoroquinolones. Clin Invest Med[J].1989, 12(1):28-34.
8. Gonzalez JP, Henwood JM:Pefloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs [J].1989,37(5):628-668.
9. 唐建华姜,刘昌林,邓开峰：氧氟沙星药物的研究进展.中国兽药杂志[J].2007, 41(9)：29-33.
10. Drew RH, Gallis HA:Ofloxacin:its pharmacology, pharmacokinetics, and potential for clinical application. Pharmacotherapy[J].1988,8(1):35-46.
11. Henwood JM, Monk JP:Enoxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs[J].1988,36(1):32-66.
12.张致平,蔡年生：依诺沙星研究新进展.中国抗生素杂志[J].1993,18(5)：324-328.
13.李德荣,刘鑫荣：依诺沙星及其与几种新喹诺酮抗菌药比较.中国抗生素杂志[J].1992,17(2)：126-129.
14. Toothaker RD:Enoxacin absorption and elimination characteristics. Clin Pharmacokinet[J].1989,16 Suppl 1:52-58.
15. Ball AP:Overview of clinical experience with ciprofloxacin. Eur J Clin Microbiol[J]. 1986,5(2):214-219.
16. Kayser FH, Novak J:In vitro activity of ciprofloxacin against gram-positive bacteria. An overview. Am J Med [J].1987,82(4A):33-39.
17. Nix DE, DeVito JM:Ciprofloxacin and norfloxacin, two fluoroquinolone antimicrobials. Clin Pharm[J].1987,6(2):105-117.
18. Oriel JD:Ciprofloxacin in the treatment of gonorrhoea and non-gonococcal urethritis. J Antimicrob Chemother[J].1986,18 Suppl D:129-132.
19. Terp DK, Rybak MJ:Ciprofloxacin. Drug Intell Clin Pharm [J].1987,21(7-8):568-574.
20. Ball P:Ciprofloxacin:an overview of adverse experiences. J Antimicrob Chemother[J]. 1986,18 Suppl D:187-193.
21. Bergan T, Dalhoff A, Rohwedder R:Pharmacokinetics of ciprofloxacin. Infection[J]. 1988,16 Suppl 1:S3-13.
22. OKEZAKI THE:In vitro and in vivo activity of NY-198, a new difluorinated quinolone. Antimicrob Agents Chemother [J].1987,31(6):854-859.
23. Morrison PJ, Mant TG, Norman GT, Robinson J, Kunka RL:Pharmacokinetics and tolerance of lomefloxacin after sequentially increasing oral doses. Antimicrob Agents Chemother[J].1988,32(10):1503-1507.
24. Stone JW, Andrews JM, Ashby JP, Griggs D, Wise R:Pharmacokinetics and tissue penetration of orally administered lomefloxacin. Antimicrob Agents Chemother[J]. 1988,32(10):1508-1510.
25. Barry AL, Jones RN:In-vitro activities of temafloxacin, tosufloxacin (A-61827) and five other fluoroquinolone agents. J Antimicrob Chemother[J].1989,23(4):527-535.
26. Fernandes PB, Chu DT, Swanson RN, Ramer NR, Hanson CW, Bower RR, Stamm JM, Hardy DJ:A-61827 (A-60969), a new fluoronaphthyridine with activity against both aerobic and anaerobic bacteria. Antimicrob Agents Chemother [J].1988,32(1):27-32.
27. Niki Y:Pharmacokinetics and safety assessment of tosufloxacin tosilate. J Infect Chemother[J].2002,8(1):1-18.
28. Rubinstein E:History of quinolones and their side effects. Chemotherapy[J].2001,47 Suppl 3:3-8; discussion 44-48.
29.张先洲,蔡鸿生,尹武华：喹诺酮类新药-替马沙星.医药导报[J].1992,11(3)：23-24.
30.刘晓园,谢淑兰：最新氟喹诺酮类药-替马沙星.江西医药[J].1993,28(2)：109-113.
31.汪友永：世界第一个被淘汰的喹诺酮类药物_替马沙星.医药导报[J].1993,12(3)：112.
32. Ravizzola G, Pinsi G, Pirali F, Colombrita D, Foresti I, Peroni L, Turano A:Rufloxacir (MF-934):in vitro and in vivo antibacterial activity. Drugs Exp Clin Res[J].1989 15(1):11-15.
33. Segre G, Cerretani D, Cerri D, Moltoni L:A new tricyclic fluoroquinolone, rufloxacir (MF-934), with interesting antibacterial and pharmacokinetic characteristics. Drugs Exp Clin Res[J].1988,14(12):747-754.
34. Manek N, Andrews JM, Wise R:In vitro activity of Ro 23-6240, a new difluoroquinolone derivative, compared with that of other antimicrobial agents. Antimicrob Agents Chemother[J].1986,30(2):330-332.
35.苗佳：新喹诺酮类抗菌药_氟罗沙星.华西医学[J].1995,10(3)：283-285.
36.高惠,戚敏：长效喹诺酮类药物-氟罗沙星(fleroxacin).山东医药工业[J].199918(5)：56-58.
37. Stobberingh EE, Houben AW, van Boven CP:In vitro evaluation of Ro 23-6240, a nev fluorinated 4-quinolone. Chemotherapy[J].1987,33(3):197-203.
38. Bowie WR, Willetts V, Jewesson PJ:Adverse reactions in a dose-ranging study with a new long-acting fluoroquinolone, fleroxacin. Antimicrob Agents Chemother[J].1989 33(10):1778-1782.
39. Nakamura S, Minami A, Nakata K, Kurobe N, Kouno K, Sakaguchi Y, Kashimoto S Yoshida H, Kojima T, Ohue T et al:In vitro and in vivo antibacterial activities o AT-4140, a new broad-spectrum quinolone. Antimicrob Agents Chemother[J].1989 33(8):1167-1173.
40.胡鹏：新喹诺酮类抗菌药司帕沙星.国外医药抗生素分册[J].1998,19(1)：65-79.
41.许铁男：新喹诺酮类抗菌药司帕沙星的药代动力学.国外医药抗生素分册[J].199617(3)：220-223.
42.方翼,王睿,周筱青：司帕沙星的光毒性及心脏毒性.解放军药学学报[J].200420(4)：286-290.
43. Yamakawa T, Mitsuyama J, Hayashi K:In vitro and in vivo antibacterial activity o T-3912, a novel non-fluorinated topical quinolone. J Antimicrob Chemother[J].2002 49(3):455-465.
44. Ward KW, Lepage JF, Driot JY:Nonclinical pharmacodynamics, pharmacokinetics, an(?) safety of BOL-303224-A, a novel fluoroquinolone antimicrobial agent for topica ophthalmic use. J Ocul Pharmacol Ther[J].2007,23(3):243-256.
45. Muto N, Mitoh Y, Yamamoto I:Development of a sensitive enzyme immunoassay fo OPC-7251, a novel antimicrobial agent for percutaneous application. J Immunoassay[J] 1990,11(1):1-16.
46. Hurst M, Lamb HM, Scott LJ, Figgitt DP:Levofloxacin:an updated review of its use ii the treatment of bacterial infections. Drugs[J].2002,62(14):2127-2167.
47.梁诚：氟喹诺酮类药物生产现状与研究进展.精细与专用化学品[J].2005,13(5)：1-4.
48.许铁男：新喹诺酮类抗菌剂格雷沙星.药学进展[J].1995,19(3)：172-174.
49. Imada T, Miyazaki S, Nishida M, Yamaguchi K, Goto S:In vitro and in vivo antibacteria activities of a new quinolone, OPC-17116. Antimicrob Agents Chemother[J].1992 36(3):573-579.
50. Ito T, Otsuki M, Nishino T:In vitro antibacterial activity of Q-35, a new fluoroquinolone Antimicrob Agents Chemother[J].1992,36(8):1708-1714.
51.王金生,宋慈媛：巴罗沙星.药学进展[J].1996,20(1)：41-45.
52. Fukuoka Y, Ikeda Y, Yamashiro Y, Takahata M, Todo Y, Narita H:In vitro and in vivo antibacterial activities of T-3761, a new quinolone derivative. Antimicrob Agents Chemother[J].1993,37(3):384-392.
53.沈奇：新氟喹诺酮类抗菌药-帕珠沙星.华西医学[J].2005,20(4)：804-805.
54. Wise R, Ashby JP, Andrews JM:In vitro activity of PD 127,391, an enhanced-spectrum quinolone. Antimicrob Agents Chemother[J].1988,32(8):1251-1256.
55. Shonekan D, Mildvan D, Handwerger S:Comparative in vitro activities of teicoplanin, daptomycin, ramoplanin, vancomycin, and PD127,391 against blood isolates of gram-positive cocci. Antimicrob Agents Chemother[J].1992,36(7):1570-1572.
56. Gooding BB, Jones RN:In vitro antimicrobial activity of CP-99,219, a novel azabicyclo-naphthyridone. Antimicrob Agents Chemother[J].1993,37(2):349-353.
57. Neu HC, Chin NX:In vitro activity of the new fluoroquinolone CP-99,219. Antimicrob Agents Chemother[J].1994,38(11):2615-2622.
58.佚名：FDA发布与曲伐沙星(Trovan)有关的肝毒性通告.世界医药[J].2001(7).
59. Fass RJ:In vitro activity of Bay 12-8039, a new 8-methoxyquinolone. Antimicrob Agents Chemother[J].1997,41(8):1818-1824.
60. Goldstein EJ, Citron DM, Hudspeth M, Hunt Gerardo S, Merriam CV:In vitro activity of Bay 12-8039, a new 8-methoxyquinolone, compared to the activities of 11 other oral antimicrobial agents against 390 aerobic and anaerobic bacteria isolated from human and animal bite wound skin and soft tissue infections in humans. Antimicrob Agents Chemother[J].1997,41(7):1552-1557.
61.张英,赵志刚,张杰：莫西沙星-一种新的氟喹诺酮类药物.中国临床药理学杂志[J].2002,18(5)：396-400.
62. Bichsel A, James CW, Gurk-Turner C:Fluoroquinolone drug class update. PHARMACOLOGY NOTES[J].2000(13):289-292.
63.谢红刚,封宇飞,邹忠梅：新一代广谱氟喹诺酮类抗菌药吉米沙星.中国新药杂志[J].2005,14(3)：353-355.
64.郎杰,孙成春：加替沙星及其应用的研究进展.实用医药杂志[J].2004,21(5)：470-471.
65.解飞,封宇飞,胡欣,傅得兴,张君仁：新氟喹诺酮类抗菌药普利沙星.中国新药杂志[J].2005,14(9)：1198-1021.
66. Blasi F:Prulifloxacin:a brief review of its potential in the treatment of acute exacerbation of chronic bronchiti:. International Journal of COPD[J].2007,2(1):27-31.
67.佚名：普卢利沙星.中国医药技术与市场[J].2004,4(5)：50-51.
68.贺娟,夏培元：普卢利沙星-新一代氟喹诺酮类抗菌药.抗感染药学[J].2006,3(1)：5-9.
69.贾立革：氟喹诺酮类抗菌药prulifloxacin.国外医学药学分册[J].1997,24(3)：182-183.
70.沈奇：新氟喹诺酮类抗菌药-Sitafloxacin的体外抗菌活性.华西医学[J].2001,16(1)：122-124.
71.柴芸：新氟喹诺酮类抗菌药西他沙星.国外医药抗生素分册[J].2009,30(6)：264-270.
72.肖永红,李耘,刘建,钟巍,杨维维：安妥沙星琼脂稀释法体外抗菌活性测定临界浓度初步研究.中国抗生素杂志[J].2010,35(6)：462-268.
73.梅友健：新型高效广谱抗菌药物-安妥沙星.安徽医药[J].2010,14(2)：229-231.
74. Karpecki TLCPM:Besifloxacin:a novel anti-infective for the treatment of bacterial conjunctivitis. Clinical Ophthalmology[J].2010,4:215-225.
75.郗砚彬,张宇,杨丽钦,寇同欣：治疗结膜炎的新喹诺酮类药物贝西沙星.中国新药杂志[J].2010,19(4)：267-269.
76.李伟：贝西沙星Besivance.中国药物化学杂志[J].2010,20(1)：78.
77. Haas W, Pillar CM, Hesje CK, Sanfilippo CM, Morris TW:Bactericidal activity of besifloxacin against staphylococci, Streptococcus pneumoniae and Haemophilus influenzae. Journal of Antimicrobial Chemotherapy[J].2010,65(7):1441-1447.
78.崔玉彬：新氟喹诺酮类DC-159a体外抗分枝杆菌活性研究.国外医药抗生素分册[J]2010,31(5)：236-237.
79. Clark C, Smith K, Ednie L, Bogdanovich T, Dewasse B, McGhee P, Appelbaum PC:In Vitro Activity of DC-159a, a New Broad-Spectrum Fluoroquinolone, Compared with That of Other Agents against Drug-Susceptible and -Resistant Pneumococci. Antimicrobial Agents and Chemotherapy[J].2007,52(l):77-84.
80.柴芸,刘明亮：新氟喹诺酮类抗菌药ABT-492.国外医药抗生素分册[J].2007,28(5)：199-201,209.
81. Almer LS, Hoffrage JB, Keller EL, Flamm RK, Shortridge VD:In Vitro and Bactericidal Activities of ABT-492, a Novel Fluoroquinolone, against Gram-Positive and Gram-Negative Organisms. Antimicrobial Agents and Chemotherapy[J].2004, 48(7):2771-2777.
82. Sillerstrom E, Wahlund E, Nord CE:In vitro activity of ABT-492 against anaerobic bacteria. J Chemother[J].2004,16(3):227-229.
83. Strahilevitz J, Hooper DC:Dual Targeting of Topoisomerase IV and Gyrase To Reduce Mutant Selection:Direct Testing of the Paradigm by Using WCK-1734, a New Fluoroquinolone, and Ciprofloxacin. Antimicrobial Agents and Chemotherapy[J].2005, 49(5):1949-1956.
84.周伟澄,周后元：氟喹诺酮类抗菌药物研究进展.中国医药工业杂志[J].2005,36(5)：309-312.
85. Otani T, Tanaka M, Ito E, Kurosaka Y, Murakami Y, Onodera K, Akasaka T, Sato K:In vitro and in vivo antibacterial activities of DK-507k, a novel fluoroquinolone. Antimicrob Agents Chemother[J].2003,47(12):3750-3759.
86. Pucci MJ, Podos SD, Thanassi JA, Leggio MJ, Bradbury BJ, Deshpande M:In Vitro and In Vivo Profiles of ACH-702, an Isothiazoloquinolone, against Bacterial Pathogens. Antimicrob Agents Chemother[J].2011,55(6):2860-2871.
87. Molina-Torres CA, Ocampo-Candiani J, Rendon A, Pucci MJ, Vera-Cabrera L:In vitro activity of a new isothiazoloquinolone, ACH-702, against Mycobacterium tuberculosis and other mycobacteria. Antimicrob Agents Chemother [J].2010,54(5):2188-2190.
88. Morrow BJ, He W, Amsler KM, Foleno BD, Macielag MJ, Lynch AS, Bush K:In Vitro Antibacterial Activities of JNJ-Q2, a New Broad-Spectrum Fluoroquinolone. Antimicrobial Agents and Chemotherapy[J].2010,54(5):1955-1964.
89.孙攀,殷瑜,陈代杰：iac(6')-Ib-cr介导的喹喏酮类新耐药机制研究进展.生命科学[J].2009,21(4)：584-588.
90.夏蕊蕊,国宪虎,张裕臻,徐海：喹诺酮类药物及细菌对其耐药性机制研究进展.中国抗生素杂志[J].2010,35(4)：255-261.
91.曾振灵,林居纯：氟喹诺酮类药物耐药性的研究进展.广州畜牧兽医科技[J].2005,30(1)：11-15.
2. 赵汝霞,虞亦鸣：喹诺酮类药物的研究进展.临床肺科杂志[J].2010,15(12)：1769-1770.
3. Drlica K, Malik M, Kerns RJ, Zhao X:Quinolone-Mediated Bacterial Death. Antimicrobial Agents and Chemotherapy[J].2007,52(2):385-392.
4. Ruiz J:Mechanisms of resistance to quinolones:target alterations, decreased accumulation and DNA gyrase protection. Journal of Antimicrobial Chemotherapy [J].2003, 51(5):1109-1117.
5. 张英,赵志刚,张杰：莫西沙星-一种新的氟喹诺酮类药物.中国临床药理学杂志[J].2002,18(5)：396-400.
6. 柴芸：新氟喹诺酮类抗菌药西他沙星.国外医药抗生素分册[J].2009,30(6)：264-270.
7. J萨姆布鲁克,DW拉塞尔：分子克隆试验指南[M].北京：科学出版社,2002.
8. CLSI. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard-eighth edition. [S] CLSI document M07-A8. Wayne, PA: Clinical and Laboratory Standards Institute,2009.
9.张丽龙；粟永萍；刘晓宏；程天民；郑虎；翁玲玲；艾国平：第三军医大学学报[J].2006,28(13)：1393-1396
10. Black MT, Stachyra T, Platel D, Girard AM, Claudon M, Bruneau JM, Miossec C: Mechanism of Action of the Antibiotic NXL101, a Novel Nonfluoroquinolone Inhibitor of Bacterial Type Ⅱ Topoisomerases. Antimicrobial Agents and Chemotherapy[J].2008, 52(9):3339-3349.
11. Yoshihiro Oyamada J-iY:Mechanism of inhibition of DNA gyrase by ES-1273, a novel DNA gyrase inhibitor. Microbiol Immunol [J].2007,50(10):977-984.
12. Mary-Ann Bjornsti and Neil Osheroff, Methods in Molecular Biology.Vol.94[M]. USA:Humana press,1999,1st edition
13. Mary-Ann Bjornsti and Neil Osheroff, Methods in Molecular Biology.Vol.95[M].USA:Humana press,1999,1st edition
14.徐佳骏,崔岚：新型喹诺酮类抗菌药加雷沙星.中国新药杂志[J].2008,17(20)：1808-1810.
15.柴芸,刘秉全,郭慧元：喹诺酮的结构修饰及药理活性研究新进展.中国新药杂志[J].2007,16(14)：1068-1074.
16.杨信怡：重组溶葡球菌酶抗菌药效学及耐药机制研究[D].北京：北京协和医学院,2005.
17.王宇明：感染病学[M].北京：人民卫生出版社2010,216-241
18.王睿：氟喹诺酮类PK-PD的研究进展.中国新药杂志[J]2002,11(11)：884-887.
19. Bichsel A, James CW, Gurk-Turner C:Fluoroquinolone drug class update. PHARMACOLOGY NOTES[J].2000(13):289-292.
20.李聪然：新氨基糖苷类抗生素威替米星的药效学及其对重组氨基糖苷类双功能修饰酶的稳定性[D]北京,北京协和医学院,2006.
21.王洪允：生物样本中药物定量分析的规范和要求.2011年高级临床药理Ⅰ期研究高级培训班[A],2011,58-94
22.杨信怡：重组溶葡球菌酶抗菌药效学及耐药机制研究[D]北京,北京协和医学院,2005.
23. Odenholt I, Cars O:Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli:simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model. Journal of Antimicrobial Chemotherapy[J] 2006,58(5):960-965.
1. 张致平：喹诺酮类抗菌药研究的进展.中国抗生素杂志[J].1992,17(2)：87-97.
2. 张致平：喹诺酮类抗菌药研究的新进展.引进国外技术与设备[J].1995,1(4)：216-222.
3. Rowen RC, Michel DJ, Thompson JC:Norfloxacin:clinical pharmacology and clinical use. Pharmacotherapy[J].1987,7(4):92-110.
4. Ito A, Hirai K, Inoue M, Koga H, Suzue S, Irikura T, Mitsuhashi S:In vitro antibacterial activity of AM-715, a new nalidixic acid analog. Antimicrob Agents Chemother[J].1980, 17(2):103-108.
5. Wang C, Sabbaj J, Corrado M, Hoagland V:World-wide clinical experience with norfloxacin:efficacy and safety. Scand J Infect Dis Suppl [J].1986,48:81-89.
6. Wise R:Norfloxacin--a review of pharmacology and tissue penetration. J Antimicrob Chemother[J].1984,13 Suppl B:59-64.
7. Ball P:Adverse reactions and interactions of fluoroquinolones. Clin Invest Med[J].1989, 12(1):28-34.
8. Gonzalez JP, Henwood JM:Pefloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs [J].1989,37(5):628-668.
9. 唐建华姜,刘昌林,邓开峰：氧氟沙星药物的研究进展.中国兽药杂志[J].2007, 41(9)：29-33.
10. Drew RH, Gallis HA:Ofloxacin:its pharmacology, pharmacokinetics, and potential for clinical application. Pharmacotherapy[J].1988,8(1):35-46.
11. Henwood JM, Monk JP:Enoxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs[J].1988,36(1):32-66.
12.张致平,蔡年生：依诺沙星研究新进展.中国抗生素杂志[J].1993,18(5)：324-328.
13.李德荣,刘鑫荣：依诺沙星及其与几种新喹诺酮抗菌药比较.中国抗生素杂志[J].1992,17(2)：126-129.
14. Toothaker RD:Enoxacin absorption and elimination characteristics. Clin Pharmacokinet[J].1989,16 Suppl 1:52-58.
15. Ball AP:Overview of clinical experience with ciprofloxacin. Eur J Clin Microbiol[J]. 1986,5(2):214-219.
16. Kayser FH, Novak J:In vitro activity of ciprofloxacin against gram-positive bacteria. An overview. Am J Med [J].1987,82(4A):33-39.
17. Nix DE, DeVito JM:Ciprofloxacin and norfloxacin, two fluoroquinolone antimicrobials. Clin Pharm[J].1987,6(2):105-117.
18. Oriel JD:Ciprofloxacin in the treatment of gonorrhoea and non-gonococcal urethritis. J Antimicrob Chemother[J].1986,18 Suppl D:129-132.
19. Terp DK, Rybak MJ:Ciprofloxacin. Drug Intell Clin Pharm [J].1987,21(7-8):568-574.
20. Ball P:Ciprofloxacin:an overview of adverse experiences. J Antimicrob Chemother[J]. 1986,18 Suppl D:187-193.
21. Bergan T, Dalhoff A, Rohwedder R:Pharmacokinetics of ciprofloxacin. Infection[J]. 1988,16 Suppl 1:S3-13.
22. OKEZAKI THE:In vitro and in vivo activity of NY-198, a new difluorinated quinolone. Antimicrob Agents Chemother [J].1987,31(6):854-859.
23. Morrison PJ, Mant TG, Norman GT, Robinson J, Kunka RL:Pharmacokinetics and tolerance of lomefloxacin after sequentially increasing oral doses. Antimicrob Agents Chemother[J].1988,32(10):1503-1507.
24. Stone JW, Andrews JM, Ashby JP, Griggs D, Wise R:Pharmacokinetics and tissue penetration of orally administered lomefloxacin. Antimicrob Agents Chemother[J]. 1988,32(10):1508-1510.
25. Barry AL, Jones RN:In-vitro activities of temafloxacin, tosufloxacin (A-61827) and five other fluoroquinolone agents. J Antimicrob Chemother[J].1989,23(4):527-535.
26. Fernandes PB, Chu DT, Swanson RN, Ramer NR, Hanson CW, Bower RR, Stamm JM, Hardy DJ:A-61827 (A-60969), a new fluoronaphthyridine with activity against both aerobic and anaerobic bacteria. Antimicrob Agents Chemother [J].1988,32(1):27-32.
27. Niki Y:Pharmacokinetics and safety assessment of tosufloxacin tosilate. J Infect Chemother[J].2002,8(1):1-18.
28. Rubinstein E:History of quinolones and their side effects. Chemotherapy[J].2001,47 Suppl 3:3-8; discussion 44-48.
29.张先洲,蔡鸿生,尹武华：喹诺酮类新药-替马沙星.医药导报[J].1992,11(3)：23-24.
30.刘晓园,谢淑兰：最新氟喹诺酮类药-替马沙星.江西医药[J].1993,28(2)：109-113.
31.汪友永：世界第一个被淘汰的喹诺酮类药物_替马沙星.医药导报[J].1993,12(3)：112.
32. Ravizzola G, Pinsi G, Pirali F, Colombrita D, Foresti I, Peroni L, Turano A:Rufloxacir (MF-934):in vitro and in vivo antibacterial activity. Drugs Exp Clin Res[J].1989 15(1):11-15.
33. Segre G, Cerretani D, Cerri D, Moltoni L:A new tricyclic fluoroquinolone, rufloxacir (MF-934), with interesting antibacterial and pharmacokinetic characteristics. Drugs Exp Clin Res[J].1988,14(12):747-754.
34. Manek N, Andrews JM, Wise R:In vitro activity of Ro 23-6240, a new difluoroquinolone derivative, compared with that of other antimicrobial agents. Antimicrob Agents Chemother[J].1986,30(2):330-332.
35.苗佳：新喹诺酮类抗菌药_氟罗沙星.华西医学[J].1995,10(3)：283-285.
36.高惠,戚敏：长效喹诺酮类药物-氟罗沙星(fleroxacin).山东医药工业[J].199918(5)：56-58.
37. Stobberingh EE, Houben AW, van Boven CP:In vitro evaluation of Ro 23-6240, a nev fluorinated 4-quinolone. Chemotherapy[J].1987,33(3):197-203.
38. Bowie WR, Willetts V, Jewesson PJ:Adverse reactions in a dose-ranging study with a new long-acting fluoroquinolone, fleroxacin. Antimicrob Agents Chemother[J].1989 33(10):1778-1782.
39. Nakamura S, Minami A, Nakata K, Kurobe N, Kouno K, Sakaguchi Y, Kashimoto S Yoshida H, Kojima T, Ohue T et al:In vitro and in vivo antibacterial activities o AT-4140, a new broad-spectrum quinolone. Antimicrob Agents Chemother[J].1989 33(8):1167-1173.
40.胡鹏：新喹诺酮类抗菌药司帕沙星.国外医药抗生素分册[J].1998,19(1)：65-79.
41.许铁男：新喹诺酮类抗菌药司帕沙星的药代动力学.国外医药抗生素分册[J].199617(3)：220-223.
42.方翼,王睿,周筱青：司帕沙星的光毒性及心脏毒性.解放军药学学报[J].200420(4)：286-290.
43. Yamakawa T, Mitsuyama J, Hayashi K:In vitro and in vivo antibacterial activity o T-3912, a novel non-fluorinated topical quinolone. J Antimicrob Chemother[J].2002 49(3):455-465.
44. Ward KW, Lepage JF, Driot JY:Nonclinical pharmacodynamics, pharmacokinetics, an(?) safety of BOL-303224-A, a novel fluoroquinolone antimicrobial agent for topica ophthalmic use. J Ocul Pharmacol Ther[J].2007,23(3):243-256.
45. Muto N, Mitoh Y, Yamamoto I:Development of a sensitive enzyme immunoassay fo OPC-7251, a novel antimicrobial agent for percutaneous application. J Immunoassay[J] 1990,11(1):1-16.
46. Hurst M, Lamb HM, Scott LJ, Figgitt DP:Levofloxacin:an updated review of its use ii the treatment of bacterial infections. Drugs[J].2002,62(14):2127-2167.
47.梁诚：氟喹诺酮类药物生产现状与研究进展.精细与专用化学品[J].2005,13(5)：1-4.
48.许铁男：新喹诺酮类抗菌剂格雷沙星.药学进展[J].1995,19(3)：172-174.
49. Imada T, Miyazaki S, Nishida M, Yamaguchi K, Goto S:In vitro and in vivo antibacteria activities of a new quinolone, OPC-17116. Antimicrob Agents Chemother[J].1992 36(3):573-579.
50. Ito T, Otsuki M, Nishino T:In vitro antibacterial activity of Q-35, a new fluoroquinolone Antimicrob Agents Chemother[J].1992,36(8):1708-1714.
51.王金生,宋慈媛：巴罗沙星.药学进展[J].1996,20(1)：41-45.
52. Fukuoka Y, Ikeda Y, Yamashiro Y, Takahata M, Todo Y, Narita H:In vitro and in vivo antibacterial activities of T-3761, a new quinolone derivative. Antimicrob Agents Chemother[J].1993,37(3):384-392.
53.沈奇：新氟喹诺酮类抗菌药-帕珠沙星.华西医学[J].2005,20(4)：804-805.
54. Wise R, Ashby JP, Andrews JM:In vitro activity of PD 127,391, an enhanced-spectrum quinolone. Antimicrob Agents Chemother[J].1988,32(8):1251-1256.
55. Shonekan D, Mildvan D, Handwerger S:Comparative in vitro activities of teicoplanin, daptomycin, ramoplanin, vancomycin, and PD127,391 against blood isolates of gram-positive cocci. Antimicrob Agents Chemother[J].1992,36(7):1570-1572.
56. Gooding BB, Jones RN:In vitro antimicrobial activity of CP-99,219, a novel azabicyclo-naphthyridone. Antimicrob Agents Chemother[J].1993,37(2):349-353.
57. Neu HC, Chin NX:In vitro activity of the new fluoroquinolone CP-99,219. Antimicrob Agents Chemother[J].1994,38(11):2615-2622.
58.佚名：FDA发布与曲伐沙星(Trovan)有关的肝毒性通告.世界医药[J].2001(7).
59. Fass RJ:In vitro activity of Bay 12-8039, a new 8-methoxyquinolone. Antimicrob Agents Chemother[J].1997,41(8):1818-1824.
60. Goldstein EJ, Citron DM, Hudspeth M, Hunt Gerardo S, Merriam CV:In vitro activity of Bay 12-8039, a new 8-methoxyquinolone, compared to the activities of 11 other oral antimicrobial agents against 390 aerobic and anaerobic bacteria isolated from human and animal bite wound skin and soft tissue infections in humans. Antimicrob Agents Chemother[J].1997,41(7):1552-1557.
61.张英,赵志刚,张杰：莫西沙星-一种新的氟喹诺酮类药物.中国临床药理学杂志[J].2002,18(5)：396-400.
62. Bichsel A, James CW, Gurk-Turner C:Fluoroquinolone drug class update. PHARMACOLOGY NOTES[J].2000(13):289-292.
63.谢红刚,封宇飞,邹忠梅：新一代广谱氟喹诺酮类抗菌药吉米沙星.中国新药杂志[J].2005,14(3)：353-355.
64.郎杰,孙成春：加替沙星及其应用的研究进展.实用医药杂志[J].2004,21(5)：470-471.
65.解飞,封宇飞,胡欣,傅得兴,张君仁：新氟喹诺酮类抗菌药普利沙星.中国新药杂志[J].2005,14(9)：1198-1021.
66. Blasi F:Prulifloxacin:a brief review of its potential in the treatment of acute exacerbation of chronic bronchiti:. International Journal of COPD[J].2007,2(1):27-31.
67.佚名：普卢利沙星.中国医药技术与市场[J].2004,4(5)：50-51.
68.贺娟,夏培元：普卢利沙星-新一代氟喹诺酮类抗菌药.抗感染药学[J].2006,3(1)：5-9.
69.贾立革：氟喹诺酮类抗菌药prulifloxacin.国外医学药学分册[J].1997,24(3)：182-183.
70.沈奇：新氟喹诺酮类抗菌药-Sitafloxacin的体外抗菌活性.华西医学[J].2001,16(1)：122-124.
71.柴芸：新氟喹诺酮类抗菌药西他沙星.国外医药抗生素分册[J].2009,30(6)：264-270.
72.肖永红,李耘,刘建,钟巍,杨维维：安妥沙星琼脂稀释法体外抗菌活性测定临界浓度初步研究.中国抗生素杂志[J].2010,35(6)：462-268.
73.梅友健：新型高效广谱抗菌药物-安妥沙星.安徽医药[J].2010,14(2)：229-231.
74. Karpecki TLCPM:Besifloxacin:a novel anti-infective for the treatment of bacterial conjunctivitis. Clinical Ophthalmology[J].2010,4:215-225.
75.郗砚彬,张宇,杨丽钦,寇同欣：治疗结膜炎的新喹诺酮类药物贝西沙星.中国新药杂志[J].2010,19(4)：267-269.
76.李伟：贝西沙星Besivance.中国药物化学杂志[J].2010,20(1)：78.
77. Haas W, Pillar CM, Hesje CK, Sanfilippo CM, Morris TW:Bactericidal activity of besifloxacin against staphylococci, Streptococcus pneumoniae and Haemophilus influenzae. Journal of Antimicrobial Chemotherapy[J].2010,65(7):1441-1447.
78.崔玉彬：新氟喹诺酮类DC-159a体外抗分枝杆菌活性研究.国外医药抗生素分册[J]2010,31(5)：236-237.
79. Clark C, Smith K, Ednie L, Bogdanovich T, Dewasse B, McGhee P, Appelbaum PC:In Vitro Activity of DC-159a, a New Broad-Spectrum Fluoroquinolone, Compared with That of Other Agents against Drug-Susceptible and -Resistant Pneumococci. Antimicrobial Agents and Chemotherapy[J].2007,52(l):77-84.
80.柴芸,刘明亮：新氟喹诺酮类抗菌药ABT-492.国外医药抗生素分册[J].2007,28(5)：199-201,209.
81. Almer LS, Hoffrage JB, Keller EL, Flamm RK, Shortridge VD:In Vitro and Bactericidal Activities of ABT-492, a Novel Fluoroquinolone, against Gram-Positive and Gram-Negative Organisms. Antimicrobial Agents and Chemotherapy[J].2004, 48(7):2771-2777.
82. Sillerstrom E, Wahlund E, Nord CE:In vitro activity of ABT-492 against anaerobic bacteria. J Chemother[J].2004,16(3):227-229.
83. Strahilevitz J, Hooper DC:Dual Targeting of Topoisomerase IV and Gyrase To Reduce Mutant Selection:Direct Testing of the Paradigm by Using WCK-1734, a New Fluoroquinolone, and Ciprofloxacin. Antimicrobial Agents and Chemotherapy[J].2005, 49(5):1949-1956.
84.周伟澄,周后元：氟喹诺酮类抗菌药物研究进展.中国医药工业杂志[J].2005,36(5)：309-312.
85. Otani T, Tanaka M, Ito E, Kurosaka Y, Murakami Y, Onodera K, Akasaka T, Sato K:In vitro and in vivo antibacterial activities of DK-507k, a novel fluoroquinolone. Antimicrob Agents Chemother[J].2003,47(12):3750-3759.
86. Pucci MJ, Podos SD, Thanassi JA, Leggio MJ, Bradbury BJ, Deshpande M:In Vitro and In Vivo Profiles of ACH-702, an Isothiazoloquinolone, against Bacterial Pathogens. Antimicrob Agents Chemother[J].2011,55(6):2860-2871.
87. Molina-Torres CA, Ocampo-Candiani J, Rendon A, Pucci MJ, Vera-Cabrera L:In vitro activity of a new isothiazoloquinolone, ACH-702, against Mycobacterium tuberculosis and other mycobacteria. Antimicrob Agents Chemother [J].2010,54(5):2188-2190.
88. Morrow BJ, He W, Amsler KM, Foleno BD, Macielag MJ, Lynch AS, Bush K:In Vitro Antibacterial Activities of JNJ-Q2, a New Broad-Spectrum Fluoroquinolone. Antimicrobial Agents and Chemotherapy[J].2010,54(5):1955-1964.
89.孙攀,殷瑜,陈代杰：iac(6')-Ib-cr介导的喹喏酮类新耐药机制研究进展.生命科学[J].2009,21(4)：584-588.
90.夏蕊蕊,国宪虎,张裕臻,徐海：喹诺酮类药物及细菌对其耐药性机制研究进展.中国抗生素杂志[J].2010,35(4)：255-261.
91.曾振灵,林居纯：氟喹诺酮类药物耐药性的研究进展.广州畜牧兽医科技[J].2005,30(1)：11-15.